Ganglioside GM3-based anticancer vaccines: Reviewing the mechanism and current strategies - Institut Parisien de Chimie Moléculaire Accéder directement au contenu
Article Dans Une Revue Biomedicine and Pharmacotherapy Année : 2024

Ganglioside GM3-based anticancer vaccines: Reviewing the mechanism and current strategies

Résumé

Ganglioside GM3 is one of the most common membrane-bound glycosphingolipids. The over-expression of GM3 on tumor cells makes it defined as a tumor-associated carbohydrate antigen (TACA). The specific expression property in cancers, especially in melanoma, make it become an important target to develop anticancer vaccines or immunotherapies. However, in the manner akin to most TACAs, GM3 is an autoantigen facing with problems of low immunogenicity and easily inducing immunotolerance, which means itself only cannot elicit a powerful enough immune response to prevent or treat cancer. With a comparative understanding of the mechanisms that how immune system responses to the carbohydrate vaccines, this review summarizes the studies on the recent efforts to development GM3-based anticancer vaccines.

Domaines

Chimie
Fichier principal
Vignette du fichier
2024, 176, 116824 Biomedicine & Pharmacotherapy.pdf (2.31 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04595768 , version 1 (05-06-2024)

Licence

Identifiants

Citer

Jiaxu Zhang, Marco Terreni, Fang Liu, Matthieu Sollogoub, Yongmin Zhang. Ganglioside GM3-based anticancer vaccines: Reviewing the mechanism and current strategies. Biomedicine and Pharmacotherapy, 2024, 176, pp.116824. ⟨10.1016/j.biopha.2024.116824⟩. ⟨hal-04595768⟩
35 Consultations
6 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More